AU5353901A - Methods of use of penicillamines for the treatment of conditions resulting from dna damage - Google Patents

Methods of use of penicillamines for the treatment of conditions resulting from dna damage

Info

Publication number
AU5353901A
AU5353901A AU5353901A AU5353901A AU5353901A AU 5353901 A AU5353901 A AU 5353901A AU 5353901 A AU5353901 A AU 5353901A AU 5353901 A AU5353901 A AU 5353901A AU 5353901 A AU5353901 A AU 5353901A
Authority
AU
Australia
Prior art keywords
penicillamines
treatment
methods
dna damage
conditions resulting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU5353901A
Inventor
Myron K Jacobson
Elaine L Jacobson
Georg T Wondrak
Daniel Cervantes-Laurean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NIADYNE CORP
University of Kentucky Research Foundation
Original Assignee
NIADYNE CORP
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NIADYNE CORP, University of Kentucky Research Foundation filed Critical NIADYNE CORP
Publication of AU5353901A publication Critical patent/AU5353901A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU5353901A 2000-04-14 2001-04-16 Methods of use of penicillamines for the treatment of conditions resulting from dna damage Pending AU5353901A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19721600P 2000-04-14 2000-04-14
PCT/US2001/012325 WO2001078718A1 (en) 2000-04-14 2001-04-16 Methods of use of penicillamines for the treatment of conditions resulting from dna damage

Publications (1)

Publication Number Publication Date
AU5353901A true AU5353901A (en) 2001-10-30

Family

ID=22728499

Family Applications (2)

Application Number Title Priority Date Filing Date
AU5353901A Pending AU5353901A (en) 2000-04-14 2001-04-16 Methods of use of penicillamines for the treatment of conditions resulting from dna damage
AU2001253539A Ceased AU2001253539B2 (en) 2000-04-14 2001-04-16 Methods of use of penicillamines for the treatment of conditions resulting from DNA damage

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001253539A Ceased AU2001253539B2 (en) 2000-04-14 2001-04-16 Methods of use of penicillamines for the treatment of conditions resulting from DNA damage

Country Status (6)

Country Link
EP (1) EP1274418A4 (en)
JP (1) JP2003530434A (en)
CN (1) CN1431898A (en)
AU (2) AU5353901A (en)
MX (1) MXPA02010182A (en)
WO (1) WO2001078718A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
JP4985214B2 (en) * 2007-08-20 2012-07-25 ソニー株式会社 Biological substance detection method using laser

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070483A (en) * 1975-06-30 1978-01-24 Sidney Lerman Method of administering a human ocular treating agent and product therefor
US5334617A (en) * 1984-03-19 1994-08-02 The Rockefeller University Amino acids useful as inhibitors of the advanced glycosylation of proteins
DE4228455A1 (en) * 1992-08-26 1994-09-15 Beiersdorf Ag Cosmetic and dermatological sunscreen formulations containing thiols and / or thiol derivatives
JPH1053516A (en) * 1996-05-20 1998-02-24 Shiseido Co Ltd Aging resistant and collagen crosslinking preventing skin lotion
PT1272843E (en) * 2000-04-14 2007-10-01 Niadyne Corp Method for identifying regulators of protein-age formation

Also Published As

Publication number Publication date
EP1274418A1 (en) 2003-01-15
CN1431898A (en) 2003-07-23
WO2001078718A1 (en) 2001-10-25
MXPA02010182A (en) 2004-08-19
JP2003530434A (en) 2003-10-14
AU2001253539B2 (en) 2005-08-04
EP1274418A4 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL151355A0 (en) Vaccine for the treatment of artherosclerosis
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
PL362855A1 (en) Improved treatment
EP1442062A4 (en) Methods for the treatment of carcinoma
PL365947A1 (en) Water filters and processes for using the same
AU2003293099A8 (en) Treatment of dna damage related disorders
AU4498201A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL155769A0 (en) Method for the treatment of inflammation
SG89379A1 (en) Treatment apparatus
PT1698338E (en) S-methyl-dihydro-ziprasidone for the treatment of schizophrenia
AU5353901A (en) Methods of use of penicillamines for the treatment of conditions resulting from dna damage
GB0130763D0 (en) Treatment methods
GB0020874D0 (en) Fluid treatment
EP1303281A4 (en) Methods of treatment
GB0031321D0 (en) Treatment
GB0116593D0 (en) Algae removal apparatus
GB2359073B (en) Fluid treatment
AU4949501A (en) Haplotypes of the pltp gene
GB9921237D0 (en) Fluid treatment
GB0001861D0 (en) Method for the treatment of obesity
GB0014904D0 (en) Methods of treatment